Alvopem(®) (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance

BACKGROUND: Lung cancer is the leading cause of cancer deaths worldwide in both men and women, and non-small cell lung cancer (NSCLC) accounts for the majority (~ 85%) of lung cancers. This post-marketing surveillance (PMS) study aimed to evaluate the safety of Pemetrexed (Alvopem(®), NanoAlvand, Ir...

Descripción completa

Detalles Bibliográficos
Autores principales: Seifi, Sharareh, Salimi, Babak, Monfared, Zahra Esfahani, Sabahi, Cyrus, Kafi, Hamidreza, Khosravi, Adnan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878795/
https://www.ncbi.nlm.nih.gov/pubmed/36698207
http://dx.doi.org/10.1186/s40545-023-00524-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878795/
https://www.ncbi.nlm.nih.gov/pubmed/36698207
http://dx.doi.org/10.1186/s40545-023-00524-5

Ejemplares similares